Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0189 • ACR Convergence 2024
Racial Discrimination Among African American Women with and Without Systemic Lupus Erythematosus (SLE)
Jessica Browder¹, Paula Ramos², Diane Kamen², Bethany Wolf², S. Sam Lim³, Lori Ann Ueberroth² and Lusawasra King², ¹Florida State University, Tallahassee, FL, ²Medical University of South Carolina, Charleston, SC, ³Emory University, Atlanta, GA
Background/Purpose: Black or African American women are disproportionately affected by SLE but remain underrepresented in research studies. To further knowledge about this health disparity group,…
Abstract Number: 0324 • ACR Convergence 2024
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Daniel Nunez¹, Jenell Volkov¹, Jason Stadanlick¹, Zachary Vorndran¹, Alexandra Ellis¹, Mallorie Werner¹, Justin Cicarelli¹, Jazmean Williams¹, Fatemeh Nezhad¹, Thomas Furmanak², Quynh Lam¹, Rebecca Estremera¹, Yvonne White¹, Jonathan Hogan¹, Claire Miller¹, Tahseen Mozaffar³, Saira Sheikh⁴, David Chang¹ and Samik Basu¹, ¹Cabaletta Bio, Philadelphia, PA, ²Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, ³The University of California, Irvine, Orange, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 0440 • ACR Convergence 2024
Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus
Jessica English¹, Bethany Wolf² and Diane Kamen², ¹Medical University of South Carolina, Johns Island, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Women with systemic lupus erythematosus (SLE) have increased rates of pre-term birth, small for gestational age babies, and pre-eclampsia compared to women without a…
Abstract Number: 0616 • ACR Convergence 2024
Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus
Victoria Delk¹, Dulaney Wilson², Gary Gilkeson², Jim Oates² and Diane Kamen², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with the potential to severely diminish patients' quality of life (QoL). SLE disproportionately affects young…
Abstract Number: 0634 • ACR Convergence 2024
Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study
Hyemin Jeong¹, Ji-Hyoun Kang¹, Sung-Eun Choi², Dong-Jin Park³ and Shin-Seok Lee⁴, ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ³Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) is a newly developed tool for assessing disease activity in SLE patients. Despite external validation in diverse…
Abstract Number: 0654 • ACR Convergence 2024
Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus
Miral Gharib¹, Georgios Baloglu Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Alemadi⁴, ¹hamad medical corporation, Doha, Qatar, ²Weill Cornell Medicine , Qatar, doha, ³Weill Cornell Medicine , Qatar, doha, Qatar, ⁴Hamad medical corporation, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms associated with poor outcomes. Small fiber neuropathy can cause intolerable…
Abstract Number: 0672 • ACR Convergence 2024
Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Ivanna Romankevych¹, Nora Singer², Kaliyani Marathe³, Angela Merritt¹, Ekemini Ogbu⁴, Chen Chen⁵, Megan Quinlan-Waters¹, Kathleen Pelletier⁶, Haihong Shi⁶, Xiaoxing Wang⁶, Bin Huang⁷ and hermine brunner⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, DC, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cin, OH, ⁶Pfizer Inc, Groton, CT, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH
Background/Purpose: Many cytokines implicated in lupus pathogenesis depend on JAK signaling to exert their intracellular action. Tofacitinib (TOFA) inhibits signaling by cytokine receptors associated with…
Abstract Number: 0887 • ACR Convergence 2024
Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort
Anastasia-Vasiliki Madenidou¹, Gillian Rice², Terence Garner³, Sarah Dyball⁴, Alice Chieng⁵, Ben Parker⁶, Tracy Briggs⁷, Adam Stevens³ and Ian Bruce⁸, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, ³Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester and Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom, ⁵Department of Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, Manchester, United Kingdom, ⁶Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁷Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, ⁸Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs) are a family of heterogeneous autoimmune diseases with overlapping clinical features. Not all patients with features suggestive of a mendelian…
Abstract Number: 1040 • ACR Convergence 2024
Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics
Jasvinder Singh¹, Larry Hearld², Walter Chatham³, Sonali Narain⁴, Narender Annapureddy⁵, Diane Kamen⁶, Kimberly Trotter⁷, vikas Majithia⁸, Cathy Lee Ching⁹, Zineb Aouhab¹⁰, Swamy Venuturupalli¹¹, Daniel Wallace¹², rosalind Ramsey-Goldman¹³, Alfred Kim¹⁴, Maureen McMahon¹⁵, S. Sam Lim¹⁶, Kalpana Bhairavarasu¹⁷, Alexa Meara¹⁸ and Kenneth Kalunian¹⁹, ¹Baylor College of Medicine, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV, ⁴Northwell Health, Great Neck, NY, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Chicago, Chicago, IL, ⁸University of Missisippi Medical Center (UMC), Jackson, MS, ⁹UMMC, Jackson, MS, ¹⁰Loyola University Medical Center, Oak Brook, IL, ¹¹Attune Health, Beverly Hills, CA, ¹²Cedars Sinai Medical Center, Studio City, CA, ¹³Northwestern University, Chicago, IL, ¹⁴Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁵UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁶Emory University, Atlanta, GA, ¹⁷Baylor College of Medicine, Sugar Land, TX, ¹⁸The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁹University of California San Diego, La Jolla, CA
Background/Purpose: To understand clinic personnel feedback regarding the implementation of a self-administered patient decision-aid (PtDA) for lupus in regular, outpatient rheumatology clinics.Methods: We provided self-administered…
Abstract Number: 1259 • ACR Convergence 2024
Adverse Childhood Experiences Are Associated with Patient-Reported Outcomes in Adolescents and Young Adults with Systemic Lupus
Tamar Rubinstein¹, Avni Dave², Terrence Calistro³, Kimberly Rapoza³, Shari Salzhauer Berkowitz³, Joyce Hui-Yuen⁴, Zanab Mian⁵, Emily Masi⁶ and Kathleen Kenney-Riley⁷, ¹Albert Einstein College of Medicine, White Plains, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Mercy University, Dobbs Ferry, NY, ⁴Northwell Health, Cohen Children's Medical Center, Great Neck, NY, ⁵Cohen Children's Medical Center, Lake Success, NY, ⁶Cohen Children's Medical Center, Floral Park, NY, ⁷Albert Einstein College of Medicine, Port Chester, NY
Background/Purpose: Adverse childhood experiences (ACEs), are major life stressors that occur before the age of 18 and include experiences of household dysfunction. Recently, prior trauma,…
Abstract Number: 1404 • ACR Convergence 2024
Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Andrew Bevan¹ and Nora Carroll², ¹Integrated Project Solutions, PPD, part of Thermo Fisher Scientific, Cambridge, United Kingdom, ²Cardiovascular and General Medicine, Thermo Fisher Scientific, Athlone, Ireland
Background/Purpose: The FDA places emphasis on studying clinically relevant trial populations but does not address how these might be defined. SLE disproportionately affects women and…
Abstract Number: 1499 • ACR Convergence 2024
Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Fumitaka Seike, Yuya Sumichika, Kenji Saito, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Although neuropsychiatric (NP) symptoms may occur in patients with SLE even in initial onset, studies regarding the distinct clinical features of SLE patients with…
Abstract Number: 1515 • ACR Convergence 2024
Incidence and Predictors of Neuropsychiatric Lupus—a Contemporary Cohort Study Across the United States
Yomaira Silva¹, Baijun Zhou¹, Grace Haeun Lee¹, Kila Panchot¹, Hyon K. Choi² and April Jorge³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with SLE can experience a variety of neuropsychiatric manifestations across 19 recognized syndromes (1999 ACR Nomenclature). Studies of neuropsychiatric SLE (NPSLE) have been…
Abstract Number: 1532 • ACR Convergence 2024
Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In October 2023, EULAR released updated recommendations for the management of SLE2. Notably, since the previous guidelines update in 2019, anifrolumab received approval for…
Abstract Number: 1552 • ACR Convergence 2024
Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Ronald Van Vollenhoven¹, Joseph Merola², Kathryn H. Dao³, Piotr Leszczynski⁴, Marilyn Pike⁵, Samantha Pomponi⁶, Coburn Hobar⁶, Matthew J. Colombo⁶, Ravi Koti⁶, Subhashis Banerjee⁶, Thomas Wegman⁷ and Eric Morand⁸, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ²UT Southwestern Medical Center, Newton, MA, ³Department of Internal Medicine, Division of Rheumatology, The University of Texas Southwestern Medical Center, Dallas, ⁴Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland, ⁵Rheumatology, MedPharm Consulting, Inc., Raleigh, NC, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Beaver Falls, PA, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].